Author's response to reviews

Title: Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

Authors:

  Wen-cong Li (nofish77@sina.com)
  Mao-rong Wang (maorongwang@gmail.com)
  Ling-bo Kong (klbdzh@163.com)
  Wei-guang Ren (renweiquang_6@163.com)
  Yu-guo Zhang (zygyxa@126.com)
  Yue-min Nan (nanyuemin@163.com)

Version: 8 Date: 8 June 2011

Author's response to reviews:

June 8, 2011

The BMC Series Editorial Production Team

Re: MS: 2986655345032012

“Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials”

We are very grateful for your letter of June 6, 2011 concerning this manuscript, and the offer to allow us to check the manuscript for typographical errors and make the final corrections or revisions. We are pleased to submit a substantially revised manuscript together with a point-by-point description of the changes made.

We appreciate this opportunity to submit a revised manuscript and trust that you will find it sufficiently improved to justify publication in BMC infectious diseases.

Yours Sincerely

Yuemin Nan (on behalf of the authors).

Response in relation to the manuscript:

2986655345032012, “Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials”

We have checked the manuscript carefully, and found three typographical errors as followed.

was changed to “Liver International 2009, 29:125-129”. We changed the format of “2009”.

(References section, page 22, line 13): “&plusmn;” was changed to “±”.

(Tables section, page 28): “Huang ZL 2010” was changed to “Huang ZL 2010”. We removed a blank space.